DexCom, Inc. (NASDAQ:DXCM) CFO Quentin S. Blackford sold 11,686 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $149.86, for a total transaction of $1,751,263.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of DXCM traded up $1.46 on Wednesday, hitting $146.70. 911,812 shares of the stock traded hands, compared to its average volume of 1,200,108. The company has a market capitalization of $13.26 billion, a PE ratio of 489.00 and a beta of 0.72. The company has a debt-to-equity ratio of 1.56, a quick ratio of 5.64 and a current ratio of 6.05. The business has a 50 day simple moving average of $160.01 and a 200 day simple moving average of $139.33. DexCom, Inc. has a one year low of $105.05 and a one year high of $178.45.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, July 31st. The medical device company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.07. The company had revenue of $336.40 million during the quarter, compared to analyst estimates of $304.40 million. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The firm’s revenue for the quarter was up 38.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.10) EPS. On average, equities analysts expect that DexCom, Inc. will post 0.94 earnings per share for the current year.
Several equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. lifted their target price on shares of DexCom from $170.00 to $190.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Canaccord Genuity upped their price target on DexCom from $160.00 to $185.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. TheStreet raised DexCom from a “d+” rating to a “c” rating in a research report on Friday, June 28th. Oppenheimer lifted their price objective on DexCom from $167.00 to $180.00 in a research note on Thursday, August 1st. Finally, Raymond James boosted their target price on DexCom from $150.00 to $172.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Six investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. DexCom presently has an average rating of “Buy” and an average price target of $168.44.
Several institutional investors have recently bought and sold shares of the business. World Asset Management Inc boosted its holdings in DexCom by 2.4% in the second quarter. World Asset Management Inc now owns 2,982 shares of the medical device company’s stock worth $447,000 after purchasing an additional 69 shares during the last quarter. First Republic Investment Management Inc. increased its position in DexCom by 3.3% during the second quarter. First Republic Investment Management Inc. now owns 3,093 shares of the medical device company’s stock valued at $463,000 after acquiring an additional 100 shares during the last quarter. OLD National Bancorp IN increased its position in shares of DexCom by 1.1% during the 2nd quarter. OLD National Bancorp IN now owns 9,838 shares of the medical device company’s stock valued at $1,474,000 after purchasing an additional 108 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of DexCom by 4.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,750 shares of the medical device company’s stock valued at $412,000 after purchasing an additional 115 shares during the last quarter. Finally, Alps Advisors Inc. lifted its stake in shares of DexCom by 3.6% in the 1st quarter. Alps Advisors Inc. now owns 3,659 shares of the medical device company’s stock worth $436,000 after purchasing an additional 126 shares during the period. 96.79% of the stock is owned by institutional investors and hedge funds.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Further Reading: How do CD ladders protect against rising interest rates?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.